CG
CALT

Cutler Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Cutler Group’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,400
Closed -$7K – 6245
2021
Q4 		$7K Buy
+1,400
New +$28.1K ﹤0.01% 4004

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cutler Group's CALT Position: Q1 2024 in Review

Cutler Group sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q1 2024, closing a stake of 100 shares — an estimated $2K sold.

Cutler Group first reported a position in CALT in Q4 2021 and held it in 5 quarters. The position peaked at $37K in Q1 2022. 19 funds tracked by Wall St. Rank hold CALT as of Q1 2024.

  • Cutler Group reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 100 Calliditas Therapeutics AB American Depositary Shares shares in Q1 2024, an estimated $2K.
  • Cutler Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q4 2021 and held it in 5 quarters.
  • Cutler Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $37K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.